Socioeconomic Disparities in Intravitreal Injection Use and Anti-VEGF Agent Selection: Aflibercept/Ranibizumab Versus Bevacizumab.
- DOI
- 10.1016/j.clinthera.2025.04.010
- Published
- 2025 Aug
- Container
- Clinical therapeutics
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.clinthera.2025.04.010,
title = {Socioeconomic Disparities in Intravitreal Injection Use and Anti-VEGF Agent Selection: Aflibercept/Ranibizumab Versus Bevacizumab.},
author = {Ko MY and Talebi R and Yu F and Tseng VL and Coleman AL and Hosseini H},
year = {2025},
journal = {Clinical therapeutics},
doi = {10.1016/j.clinthera.2025.04.010},
url = {https://doi.org/10.1016/j.clinthera.2025.04.010}
}RIS
TY - JOUR TI - Socioeconomic Disparities in Intravitreal Injection Use and Anti-VEGF Agent Selection: Aflibercept/Ranibizumab Versus Bevacizumab. AU - Ko MY AU - Talebi R AU - Yu F AU - Tseng VL AU - Coleman AL AU - Hosseini H PY - 2025 JO - Clinical therapeutics DO - 10.1016/j.clinthera.2025.04.010 UR - https://doi.org/10.1016/j.clinthera.2025.04.010 ER -
APA
MY, K., R, T., F, Y., VL, T., AL, C., & H, H. (2025). Socioeconomic Disparities in Intravitreal Injection Use and Anti-VEGF Agent Selection: Aflibercept/Ranibizumab Versus Bevacizumab.. Clinical therapeutics. https://doi.org/10.1016/j.clinthera.2025.04.010
Source records
- pubmed · retrieved 2026-09-27T17:50:06.064Z
- europe-pmc · retrieved 2026-09-27T17:50:06.083Z